Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022002867 - ANTIVIRAL PHARMACEUTICAL COMPOSITION

Publication Number WO/2022/002867
Publication Date 06.01.2022
International Application No. PCT/EP2021/067731
International Filing Date 28.06.2021
IPC
A61K 31/737 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
A61K 36/03 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
02Algae
03Phaeophycota or phaeophyta (brown algae), e.g. Fucus
A61K 9/08 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • GSK CONSUMER HEALTHCARE SARL [CH]/[CH]
Inventors
  • LOMBARDI, Maria Stella
  • BULSARA, Pallav Arvind
Agents
  • GUNDEL, Isabelle
Priority Data
20183324.130.06.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIVIRAL PHARMACEUTICAL COMPOSITION
(FR) COMPOSITION PHARMACEUTIQUE ANTIVIRALE
Abstract
(EN) Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of coronavirus infection in a human. Particularly, the viral infection is OC43 or SARS-CoV-1 or SARS-CoV-2 infection. There are also described Pharmaceutical compositions comprising fucoidan for use in a method for prevention coronavirus spread in a human population, wherein subjects of the population are tested for infection with OC43 or SARS-CoV-1 or SARS-CoV-2 and infected subjects are treated with intranasal administration of the Pharmaceutical composition.
(FR) L'invention concerne des compositions pharmaceutiques comprenant du fucoïdane destinées à être utilisées dans une méthode de traitement ou de prévention, par administration intranasale, d'une infection à coronavirus chez un être humain. En particulier, l'infection virale est l'infection par OC43 ou SARS-CoV-1 ou SARS-CoV-2. L'invention concerne également des compositions pharmaceutiques comprenant du fucoïdane destinées à être utilisées dans une méthode de prévention de la propagation de coronavirus dans une population humaine, les sujets de la population étant testés pour une infection par OC43 ou SARS-CoV-1 ou SARS-CoV-2 et des sujets infectés étant traités par administration intranasale de la composition pharmaceutique.
Related patent documents
Latest bibliographic data on file with the International Bureau